ZolgensmaMeSH Supplementary Concept

https://ansm.sante.fr/tableau-marr/onasemnogene-abeparvovec
2023
false
false
false
France
French
guidelines for drug use
risk management
Zolgensma
onasemnogene abeparvovec
infusions, intravenous
patients guideline
child
spinal muscular atrophies of childhood
onasemnogene abeparvovec-xioi
biological products
recombinant fusion proteins

---
https://www.has-sante.fr/jcms/p_3442932/fr/zolgensma-onasemnogene-abeparvovec-amyotrophie-spinale
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
onasemnogene abeparvovec-xioi
onasemnogene abeparvovec
5q spinal muscular atrophy
gene therapy
infusions, intravenous
evaluation of the transparency committee
spinal muscular atrophies of childhood
Zolgensma

---
https://www.has-sante.fr/jcms/p_3291799/fr/zolgensma-onasemnogene-abeparvovec
2022
France
evaluation of the transparency committee
Zolgensma
Zolgensma

---
https://ansm.sante.fr/informations-de-securite/zolgensma-r-onasemnogene-abeparvovec-risque-de-microangiopathie-thrombotique
2021
false
false
false
France
French
pharmacovigilance note
Onasemnogene Abeparvovec
onasemnogene abeparvovec
thrombotic microangiopathies
gene therapy
spinal muscular atrophies of childhood
infusions, intravenous
guidelines for drug use
drug monitoring
continuity of patient care
infant
onasemnogene abeparvovec-xioi
genetic therapy
Zolgensma
biological products
recombinant fusion proteins

---
https://ansm.sante.fr/tableau-atu-rtu/zolgensma-2-x-1013-genomes-de-vecteur-ml-solution-pour-perfusion
2021
false
true
false
France
French
Onasemnogene Abeparvovec
Onasemnogene Abeparvovec
summary of product characteristics
package leaflet
guidelines for drug use
onasemnogene abeparvovec
spinal muscular atrophies of childhood
HMN (Hereditary motor neuropathy) proximal type I
infusions, intravenous
onasemnogene abeparvovec-xioi
Zolgensma
biological products
recombinant fusion proteins

---
https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
2020
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Onasemnogene abeparvovec (substance)
Onasemnogene abeparvovec (substance)
gene therapy
spinal muscular atrophies of childhood
muscular atrophy, spinal
mutation
orphan drug production
infusions, intravenous
SMN complex proteins
onasemnogene abeparvovec
Product containing only onasemnogene abeparvovec in parenteral dose form (medicinal product form)
product surveillance, postmarketing
SMN1 Gene
SMN2 Gene
drug evaluation, preclinical
infant
child, preschool
HMN (Hereditary motor neuropathy) proximal type I
onasemnogene abeparvovec-xioi
genetic therapy
spinal muscular atrophies of childhood
Zolgensma
biological products
recombinant fusion proteins

---
https://www.has-sante.fr/jcms/p_3224937/fr/zolgensma
2020
false
false
false
France
French
treatment outcome
insurance, health, reimbursement
Onasemnogene abeparvovec (substance)
evaluation of the transparency committee
5q spinal muscular atrophy
spinal muscular atrophies of childhood
gene therapy
orphan drug production
infusions, intravenous
SMN1 Gene
mutation
HMN (Hereditary motor neuropathy) proximal type I
infant
Product containing only onasemnogene abeparvovec in parenteral dose form (medicinal product form)
onasemnogene abeparvovec
onasemnogene abeparvovec-xioi
genetic therapy
Zolgensma
biological products
recombinant fusion proteins

---
https://www.prescrire.org/fr/3/31/58118/0/NewsDetails.aspx
2019
false
true
false
France
French
french abstract
Onasemnogene Abeparvovec
gene therapy
HMN (Hereditary motor neuropathy) proximal type I
infant
onasemnogene abeparvovec-xioi
genetic therapy
spinal muscular atrophies of childhood
Zolgensma
biological products
recombinant fusion proteins

---